Mass molecular testing for COVID19 using NGS-based technology and a highly scalable workflow

2.1. General workflow

We have developed a complete workflow to execute the NGS-based testing, including wet-lab and bioinformatics analyses, as shown in Figure 1. This workflow is highly scalable in order to avoid bottlenecks and to increase testing capacity. Wet-lab steps may be automated by pipetting robots, and bioinformatics analyses may be performed by a very time and cost-efficient pipeline implemented through VarsVID® on Varstation® online platform.

• Download figure
• Open in new tab

Figure 1:

Panoramic view of the COVID19 NGS-based test reported in this work.

2.2. Samples and previous results

A total of 269 samples with previous results for COVID19 qRT-PCR were deidentified and selected from routine testing at the Laboratorio de Tecnicas Especiais (LATE), Hospital Israelita Albert Einstein (São Paulo, Brazil). qRT-PCR routine assays were performed using XGEN MASTER COVID-19 kit (Mobius Life Science), which uses a protocol for amplification of fragments of the genes N and ORF1ab. From the 269 samples, 112 tested positive for SARS-CoV-2 with CTs values for gene N ranging from 13 to 35.24. Remaining 157 samples tested negative. We have also included negative plaque-controls with nuclease-free water to assess cross-contamination among plaques or other sequencing artefacts. Finally, AMPLIRUN Coronavirus RNA quantified commercial SARS-CoV-2 control (Vircell Microbiologists, Spain) was serially diluted and tested for assessing limit of detection (LoD). Clinical samples presented in this work were used according to approval of the Hospital Ethical Committee under report #4.178.076.

2.3. RNA extractions and internal controls

Total RNA was extracted using the QuickExtract DNA Extraction Solution (Lucigen, WI, USA) according to the manufacturer’s instructions. MS2 phage RNA spike-in was added after extraction to function as an additional routine internal control of true negative samples, i.e., negative samples that do not yield MS2 sequences after bioinformatics analyses will be automatically placed for repetition.

2.4. Amplicon generation by RT-PCR

RT-PCR reactions for individual patient samples were performed using SuperScript™ III One-Step RT-PCR (Invitrogen) with a combination of multiplex primers designed to amplify highly conserved regions of SARS-CoV-2 and MS2 control genomes. Several target and control primers were tested for efficiency and multiplex compatibility and sequences are subject to intellectual property. Assays were carried out following standard protocols recommended for the kit: 11 μL template RNA, 2 μL SuperScript™ III RT/Platinum™ Taq Mix (Thermo Fisher Scientific, Waltham, MA), 25 μL 2X Reaction Mix (Thermo Fisher Scientific, Waltham, MA), 1 μL of each primer 10 μM (multiplex primer 1 forward, multiplex primer 1 reverse, multiplex primer 2 forward, multiplex primer 2 reverse), 0.5 μL of internal control primer forward 10 μM, 0.5 μL of internal control primer reverse 10 μM and 7 μL nuclease-free water for a final reaction volume of 50 μL. The RT-PCR reactions were incubated using the following cycling conditions: 56°C for 15 minutes, followed by one cycle of 94°C for 2 minutes, followed by 40 cycles of 94°C for 15 seconds, 65°C for 30 seconds and 72°C for 5 seconds and followed by one cycle of 72°C for 5 minutes.

2.5. Library generation

Each patient’s set of individually amplified fragments for SARS-CoV-2 and MS2 genomes was combined in a pool using the Biomek FX Automation (Beckman Coulter). After pool combination, libraries were built using KAPA HiFi Hot Start Enzyme (Roche) and Illumina Nextera XT v2 Index kit set A/B/C/D (Illumina, San Diego, CA, United States). Reaction was carried out with 5 μL cDNA, 25 μL KAPA HiFi Hot Start Enzyme, 5 μL Index i5, 5 μL Index i7, 10 μL nuclease-free water for a final reaction volume of 50 μL. The following cycles were used for the PCR reactions: 95°C for 3 minutes, followed by 8 cycles of 95°C for 30 seconds, 55°C for 30 seconds and 72°C for 5 minutes and followed by one cycle of 72°C for 5 minutes.

2.6. Library purification and normalization

Library purification were performed in the Biomek FX Automation (Beckman Coulter) using Agencourt AMPure XP Beads (Beckman Coulter®) following standard protocols. For normalization, all libraries were quantified by Qubit Fluorometer using Qubit™ dsDNA HS Assay Kit (Thermo Fisher Scientific, Waltham, MA) and size assessment was performed on Agilent 2200 TapeStation system for a dilution of 4nM. Each 4nM pool was combined into one pool and submitted to sequencing.

2.7. Sequencing

Sample pools were diluted to 2 nM based on the Qiaseq Library Quant Assay Kit (Qiagen) measurements and the size information was performed on Agilent 2200 TapeStation system. For the pool denaturation, 10 μL of the 2 nM pool was added with 10 μL of 0.2 N NaOH, after 10uL de Tris-HCl pH7 200mM was added to stop the denaturation process. 970 μL of Illumina’s HT1 buffer was add to the pool for dilute it to 20 pM and after 117uL of 20 pM pool was add to 1.183uL of Illumina’s HT1 buffer to dilute it to 1.8 pM. Diluted pool was spiked with 15% PhiX and sequenced using a Nextseq 500/550 Mid Reagent Cartridge v2 300 cycles (Illumina, San Diego, CA).

2.8. Analyses

Sequencing results were analyzed by a pipeline developed specifically for this highly scalable assay, which performs the general steps of (1) First demultiplexing (2) Quality Control, (3) Mapping to references (4) Assessing reads aligned to targets and (5) Second demultiplexing to generate patient’s individual qualitative results. More specifically, raw sequencing data is demultiplexed using Illumina’s tool blc2fastq with barcode mismatches set to 0 and other parameters set to default. Quality control is performed by cutadapt filtering to size (>50bp), average quality (Q_p > 20) and using trimming options to remove NextSeq’s biased low-quality ends. Mapping to references were carried out using bwa-mem tool (default parameters) with SARS-CoV-2 isolate Wuhan-Hu-1 (NC_045512.2) and Phage MS2 (NC_001417.2) as pathogen reference and internal control spike-in, respectively. Reads aligned to target were assessed using Bedtools and qualitative results were generated based on a threshold of reads (≥ 10) and on the decision-table shown in Table 1. A quantitative value was calculated for each positive viral target based on abundance of reads. This metric was termed Fragments per Million (FPM) and is related to similar metrics used in the scientific community for NGS analyses (FPKM, RPKM, etc.). An additional normalization for amplicon length was not necessary, considering that all amplicons were designed to have the same size. FPM values were compared with CT values and Pearson correlation coefficient was calculated. FPM is calculated as follows:

3.1. Performance results

In this work, we show a new amplicon-based methodology to amplify highly conserved regions of the SARS-CoV-2 genome and to identify these fragments using NGS sequencing. A total of 269 clinical samples with previous results for COVID19 RT-PCR were tested and performance results are summarized as follows. From 112 samples which were SARS-Cov-2 positive in RT-PCR, 102 were confirmed by NGS. From 157 samples RT-PCR that tested negative, NGS results confirmed 156. These numbers show that the NGS-based technique has overall accuracy of 95.9%, with 91.1% and 99.4% of sensitivity and specificity, respectively. Based on these results we also calculated the positive predictive value (PPV) and the negative predictive value (NPV). PPV value was 99% (102 NGS true positive and 1 NGS false positive) and NPV value was 94% (156 true negatives and 10 false negatives) (Figure 2). We noted that most false negative results presented RT-PCR CT values higher than 30 (6 false negatives). Sensitivity and specificity for samples with CT values lower than 30 were 96.1% and 99.4%, respectively. Accuracy for samples with CT values lower than 30 hitched 98,1% (Figure 2). Average SARS-CoV-2 target NGS coverage for positive samples was 25,172x.

• Download figure
• Open in new tab

Figure 2:

Accuracy, sensitivity, specificity, PPV and NPV percent of SARS-CoV-2 NGS based tested for all samples and for samples with gene N CT values lower than 30.

Positive samples presented average FPM of 2.14 × 10⁵, while average CT for gene N was 24.4. Pearson correlation coefficient between values of CT and FPM was PCC=-0.89 (p-value < 0.001), suggesting that FPM may very well reflect CT values. FPM values of the quantified spike-in controls presented low variance among samples tested, averaging 1.42 × 10⁸ with standard deviation of ± 0.58 × 10⁸. Therefore, we propose this new metric to be associated with qualitative NGS results in the same way as CT values are associated with RT-PCR. FPM values may provide patient and physician an important semi-quantitative idea of viral loads to guide clinical responses. It is important to note, though, that FPM values may vary according to the viral target (Spike, N, Matrix, etc.) and that one target may be more sensitive than others as occurs with RT-PCR.

NGS testing of the AMPLIRUN Coronavirus RNA quantified commercial SARS-CoV-2 control (Vircell Microbiologists, Spain), shows that dilutions from 1 × 10³ copies/mL to 1 × 10⁵ copies/mL were successfully identified in replicates by the technique presented in this work. Therefore, we defined 1 × 10³ copies/mL as the limit of detection.

3.2. Automation and user-friendly results using the VarsVID® platform

As this test was intended to process thousands of samples per run, we anticipated an enormous struggle to organize and perform wet-lab assays. To address this potential bottleneck, we have developed an online platform called VarsVID® to automate the entire process of sample registrations and generation of worksheets. Partner laboratories using VarsVID® will only need to provide a csv file with sample relevant information in order to plan a run and generate worksheets. These worksheets were intended to help the wet-lab professional and to avoid planning mistakes. VarsVID® will also provide a SampleSheet for Illumina sequencing, so that the professional will not waste unnecessary time registering hundreds of libraries in the basespace platform.

Bioinformatics analyses may also be performed using the VarsVID® platform, which was planned to be cloud-based and highly elastic according to laboratory requirements. These efforts resulted in the analyses of hundreds of samples FASTQs in a matter of minutes. Finally, VarsVID® provides user-friendly online results in a dash board, as well as the possibility of generating csv files for further processing.